CSIMarket
 


Stemline Therapeutics Inc  (STML)
Other Ticker:  
 
 

STML's Revenue Growth by Quarter and Year

Stemline Therapeutics Inc's Revenue results by quarter and year




STML Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - 11.83 0.20 -
III Quarter September - 13.33 - 0.30
II Quarter June - 13.01 0.50 0.30
I Quarter March 8.87 5.05 - 0.30
FY   8.87 43.22 0.70 0.90



STML Revenue first quarter 2020 Y/Y Growth Comment
Stemline Therapeutics Inc achieved in the first quarter, above Company average Revenue rise of 75.7% year on year, to $ 8.87 millions.

Looking into first quarter results within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue growth. While Stemline Therapeutics Inc' s Revenue jump of 75.7% ranks overall at the positon no. 237 in the first quarter.




STML Revenue ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - 5815 % - -
III Quarter September - - - 0 %
II Quarter June - 2502 % 66.67 % 25 %
I Quarter March 75.7 % - - 42.86 %
FY   - 6074.29 % -22.22 % -14.29 %

Financial Statements
Stemline Therapeutics Inc's first quarter 2020 Revenue $ 8.87 millions STML's Income Statement
Stemline Therapeutics Inc's first quarter 2019 Revenue $ 5.05 millions Quarterly STML's Income Statement
New: More STML's historic Revenue Growth >>


STML Revenue (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - -11.25 % - -
III Quarter September - 2.46 % - 0 %
II Quarter June - 157.62 % - 0 %
I Quarter March -25 % 2425 % - 0 %
FY (Year on Year)   - 6074.29 % -22.22 % -14.29 %




Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #86
Overall #237

Revenue Y/Y Growth Statistics
High Average Low
36.81 % 14.1 % -0 %
(Dec 31 2019)  
Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #86
Overall #237
Revenue Y/Y Growth Statistics
High Average Low
36.81 % 14.1 % -0 %
(Dec 31 2019)  

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Stemline Therapeutics Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2416.71 % 114.64 % -100 %
(Mar 31 2019)  


STML's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Stemline Therapeutics Inc disclosed fall in Revenue sequentially by -25% to $ 8.87 millions, from $ 11.83 millions released in the previous qaurter.

Albeit seasonal circumstance commonly elevate I. Quarter 2020 results, that plainly has not been substantial to salvage STML's I. Quarter achievement, Shaurya Mehta , Major Pharmaceutical Preparations industry contributor based in Toronto wrote and continued that average sequential Revenue growth is at 114.64% for STML.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Revenue quarter on quarter growth. While Stemline Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 2085.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #270
Overall #2085
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #270
Overall #2085
Revenue Q/Q Growth Statistics
High Average Low
2416.71 % 114.64 % -100 %
(Mar 31 2019)  


STML's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Stemline Therapeutics Inc realized fall in Revenue from the forth quarter by -25% to $ 8.87 millions, from $ 11.83 millions declared in the previous reporting period.

Although seasonal factors normally energize I. Quarter 2020 results, that simply could not be sufficient to salvage STML's I. Quarter performance, Shaurya Mehta , Major Pharmaceutical Preparations industry contributor based in Toronto said.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Revenue quarter on quarter growth. While Stemline Therapeutics Inc's Revenue growth quarter on quarter, overall rank is 2085.


Stemline Therapeutics Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Dec 31 2018)
Cumulative Revenue 12 Months Ending $ 47.04 $ 43.22 $ 31.59 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 8.85 % 36.81 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 419 # 284 # # #




Cumulative Revenue growth Comment
Stemline Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 75.7% year on year, to $ 47 millions if the fiscal year would have ended in Mar 31 2020.
Stemline Therapeutics Inc's trailing twelve months Revenue growth was higher than company's average 69.82% and higher than % growth in Dec 31 2019. And, Stemline Therapeutics Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But sequential rise was slower at 8.85 % from $43.22 millions achieved in the period from Dec 31 2019 to Dec 31 2018 Shaurya Mehta  went on.
It appears to be slowdown developing, more noticeable if you pay attention to the average Q/Q TTM Revenue rise what is stronger at14.1% Shaurya Mehta  wrote.

Stemline Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
36.81 %
14.1 %
-0 %
(Dec 31 2019)  

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
100.08 %
69.82 %
26.38 %
(Sep. 30, 2015)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 128
S&P 500 # 417
Cumulative Revenue growth Comment
Stemline Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 75.7% year on year, to $ 47 millions if the fiscal year would have ended in Mar 31 2020.
Stemline Therapeutics Inc's trailing twelve months Revenue growth was higher than company's average 69.82% and higher than % growth in Dec 31 2019. And, Stemline Therapeutics Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended Dec 31 2019 increase was beneth at 8.85 % from $43.22 millions reported in the period from Dec 31 2019 to Dec 31 2018.
It appears to be drop-off in progress, more obvious if you pay attention to the typical sequential Revenue advancement what is stronger at14.1% Shaurya Mehta  wrote.

Stemline Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
36.81 %
14.1 %
-0 %
(Dec 31 2019)  


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
100.08 %
69.82 %
26.38 %
(Sep. 30, 2015)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 128
S&P 500 # 417




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
STML's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for STML's Competitors
Revenue Growth for Stemline Therapeutics Inc's Suppliers
Revenue Growth for STML's Customers

You may also want to know
STML's Annual Growth Rates STML's Profitability Ratios STML's Asset Turnover Ratio STML's Dividend Growth
STML's Roe STML's Valuation Ratios STML's Financial Strength Ratios STML's Dividend Payout Ratio
STML's Roa STML's Inventory Turnover Ratio STML's Growth Rates STML's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2020
Quest Patent Research Corp  132.11 %$ 132.111 millions
Unum Therapeutics Inc   130.30 %$ 130.298 millions
Arbutus Biopharma Corp  119.59 %$ 119.588 millions
Homology Medicines Inc   117.78 %$ 117.778 millions
Momenta Pharmaceuticals inc   116.12 %$ 116.120 millions
Exact Sciences Corporation  114.65 %$ 114.647 millions
Sintx Technologies Inc   113.40 %$ 113.402 millions
Hartman Vreit Xxi Inc   113.00 %$ 113.005 millions
Amarin Corp Plcuk  111.51 %$ 111.514 millions
Biolife Solutions Inc  110.78 %$ 110.780 millions
Shockwave Medical Inc   109.07 %$ 109.066 millions
Amyris Inc   102.66 %$ 102.658 millions
Redhawk Holdings Corp   102.12 %$ 102.124 millions
Ultragenyx Pharmaceutical Inc   99.81 %$ 99.807 millions
Fortress Biotech Inc   99.44 %$ 99.444 millions
Geovax Labs Inc   96.57 %$ 96.572 millions
Myos Rens Technology Inc   94.63 %$ 94.631 millions
Biodelivery Sciences International Inc   93.63 %$ 93.626 millions
Celldex Therapeutics Inc   91.44 %$ 91.439 millions
Flexion Therapeutics Inc   90.52 %$ 90.524 millions
Dynavax Technologies Corp  89.14 %$ 89.139 millions
Aerie Pharmaceuticals Inc   87.44 %$ 87.440 millions
Misonix Inc  87.33 %$ 87.332 millions
Athenex Inc   85.46 %$ 85.463 millions
Guardant Health Inc   84.18 %$ 84.177 millions
Bristol Myers Squibb Co  82.11 %$ 82.111 millions
Catasys Inc   81.15 %$ 81.148 millions
Genmark Diagnostics Inc   79.92 %$ 79.919 millions
Nektar Therapeutics  79.20 %$ 79.197 millions
Electrocore Inc   79.14 %$ 79.143 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CPLG's Profile

Stock Price

CPLG's Financials

Business Description

Fundamentals

Charts & Quotes

CPLG's News

Suppliers

CPLG's Competitors

Customers & Markets

Economic Indicators

CPLG's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071